SV

Street Verdict

Analyst Scorecard

A record of what Marketsmith India Analysis said publicly, with the source. Not advice.

“Bullish on GlaxoSmithKline Pharmaceuticals Ltd, recommending a buy at ₹3,156 with a target price of ₹3,560 in two to three months and a stop loss at ₹2,990. The recommendation is based on the company's focus on innovation, strong financial position, operational excellence, and supply chain strength.”

Marketsmith India Analysis’s track record (trackable calls only): 322 graded calls · 95% CI 22–32%

GlaxoSmithKline Pharmaceuticals LtdBullishCalled 25 Jul 2025Graded 01 Aug 2025
Verdict:MISS

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.

Entry: ₹3,156, as stated.

Target ₹3,560, stop ₹2,990, as stated.

Window: 90 days, the time frame the call states ("two to three months").

The stop ₹2,990 was reached on a close before the target ₹3,560. Miss.

The grader’s working: R3 TRADE_SETUP: entered ₹3156 on 2025-07-28 (stated entry ₹3156, LEVEL_CMP entry, filled); stop ₹2990 breached at close ₹2936.5 on 2025-08-01. Window 90 days — rule H1: the quote states "two to three months".

How it played out

How this is worked out
Target or stop first
The stop was reached on a close before the target was.
Time to target
The target was not reached on a close inside the window.
Worst close against it
The closing price went as far as 6.96% against the call up to 1 Aug 2025, when the call was decided, measured from the entry price. Closing prices only; an intraday dip is never counted.

From the entry the grade used, on closing prices. This is a record of one past call and is not advice.

Tracking GlaxoSmithKline Pharmaceuticals Ltd since this call

1-year tracking window
Read the original articleSee Marketsmith India Analysis’s full track record